RAF 265 is a multikinase inhibitor that has displayed BRAF inhibiting activity in clinical trials. It could be used in the treatment of a subpopulation of human melanoma tumors. Has cytotoxic effect of on MDA-MB-231 cells. RAF265 when used with BEZ-235 inhibited ERK, PI3K signaling that reduced growth, proliferation and development of drug resistance in human thyroid cancer cells.

CAS：927880-90-8
中文别名：
英文别名：{1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yIoxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine;{1-Methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethylphenyl)-amine;1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine;,CHIR-265,,CHIR265;RAF265;RAF265(CHIR-265);1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine;CHIR265;
分子式：C24H16F6N6O
分子量：518.414
精确质量：518.129
Psa：80.65
Logp：7.0049

MDL号：MFCD16659061

密度：1.5±0.1g/cm3
沸点：667.6±65.0°Cat760mmHg
闪点：357.5±34.3°C
外观性状：粉末
蒸汽压：0.0±2.0mmHgat25°C
折射率：1.622
储存条件：-20℃